You are here: Industry Insights > psoriatic arthritis

News List

The NICE recommends Rinvoq for psoriatic arthritis patients pharmatimes
January 10, 2022
The chronic, inflammatory disease affects an estimated 24 in every 10,000 people.
Positive Top-Line Results from Bimekizumab Phase 3 Psoriatic Arthritis Study Demonstrated Significant Improvements in Joint and Skin Symptoms prnewswire
November 22, 2021
UCB, a global biopharmaceutical company, today announced positive top-line interim analysis results from the Phase 3 BE OPTIMAL study assessing the efficacy and safety of bimekizumab, a dual IL-17A and IL-17F inhibitor...
XELJANZ (tofacitinib citrate) Receives Marketing Authorization in the European Union for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis firstwordpharma
August 23, 2021
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has approved XELJANZ® (tofacitinib) for the treatment of active polyarticular juvenile idiopathic arthritis (JIA) and juvenile psoriatic arthritis (PsA) in patients two years.
AbbVie presents applications to FDA and EMA for approval of SKYRIZI in psoriatic arthritis pharmaceutical-business-review
April 09, 2021
AbbVie has submitted applications seeking approval for SKYRIZI (risankizumab-rzaa, 150 mg) and SKYRIZI (risankizumab, 150 mg) to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), respectively, for the treatment of ...
Skyrizi bags positive psoriatic arthritis results pharmatimes
January 08, 2021
AbbVie and Boehringer Ingelheim’s Skyrizi (risankizumab) has scored positive top-line results from two phase III studies in adults with active psoriatic arthritis.
CHMP Recommends Approvals of RINVOQ for the Active Psoriatic Arthritis, Ankylosing Spondylitis americanpharmaceuticalreview
December 31, 2020
AbbVie announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of RINVOQ™ (upadacitinib, 15 mg), an oral, once daily selective and reversible JAK inhibitor, for the expanded ...
Novartis’ Cosentyx reduces synovitis in new psoriatic arthritis study pharmatimes
November 06, 2020
Novartis’ interleukin-17A (IL-17A) Cosentyx (secukinumab) demonstrated early synovitis reduction in patients with active psoriatic arthritis in the phase IIIb ULTIMATE study.
Tremfya Approved by FDA as Selective Interleukin (IL)-23 Inhibitor for Psoriatic Arthritis americanpharmaceuticalreview
July 22, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by ...
Janssen's Tremfya wins psoriatic arthritis approval pharmatimes
July 16, 2020
Janssen's Tremfya (guselkumab) has been approved in the US as the first selective interleukin (IL)-23 inhibitor for adults with active psoriatic arthritis (PsA).
AbbVie Submits Regulatory Applications to FDA, EMA for Psoriatic Arthritis Treatment americanpharmaceuticalreview
June 15, 2020
AbbVie has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for RINVOQ™ (upadacitinib; 15 mg, once daily), a selective and reversible JAK inhibitor ...

Previous page 1 2 3 Next page